uniQure (QURE) is in focus after first quarter results showed revenue of US$3.56 million and a net loss of US$53.54 million, alongside fresh regulatory progress for its Huntington’s disease gene therapy, AMT-130.

The stock has reacted strongly to the recent earnings update and regulatory progress on AMT-130, with a 1-month share price return of 79.84% and a 1-year total shareholder return of 110.34%, which may indicate building momentum rather than a short-lived bounce.

If uniQure’s move has your attention, this can be a moment to expand your watchlist with other healthcare opportunities, including gene therapy and neurology focused companies, via 34 healthcare AI stocks

After such a sharp move and with analysts’ price targets still above the current US$27.66 share price, the key question is whether uniQure is still trading below its potential or if the market is already pricing in future growth.

Most Popular Narrative: 28.1% Undervalued

Against the last close of $27.66, the most followed narrative points to a fair value of $38.48, which assumes a high bar for future performance and regulatory success.

The potential accelerated approval for AMT-130 in treating Huntington's disease could significantly boost future revenues as it would be one of the first disease-modifying treatments available for this condition.

Expansion of the clinical pipeline with new studies in refractory temporal lobe epilepsy, Fabry disease, and SOD1-ALS could lead to additional revenue streams if these treatments are successful and commercialized.

The fair value hinges on rapid revenue expansion, a sharp swing in profit margins, and a future earnings multiple usually reserved for standout growth stories. Curious which assumptions drive that outcome and how sensitive the valuation is to shifts in trial success and timelines? The narrative lays out the full set of moving parts and how they add up to that price target.

Result: Fair Value of $38.48 (UNDERVALUED)

However, the fair value case still leans heavily on AMT-130’s regulatory path, while revenue pressure and a shift to external manufacturing could both unsettle that story.

Next Steps

With such a mixed set of signals, it helps to move quickly and stress test the upside and downside for yourself using our breakdown of 1 key reward and 4 important warning signs.

Looking for more investment ideas?

If uniQure is on your radar, do not stop here. Broaden your opportunity set with focused stock lists that match clear, thoughtful criteria.

• Target potential value opportunities by scanning companies that screen well on quality and pricing using 49 high quality undervalued stocks.
• Prioritise resilience by reviewing stocks that combine defensive characteristics with low risk scores via 71 resilient stocks with low risk scores.
• Hunt for lesser known opportunities by checking a screener containing 21 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.